Articles tagged with: Darzalex
News»
Daratumumab continues to show promise for relapsed and refractory multiple myeloma patients. Results from a Phase 1/2 study indicate that daratumumab may be effective and safe in heavily pretreated patients.
In particular, daratumumab's activity as an anti-myeloma agent seems at least as good as that of the newest myeloma therapies.
“The response to daratumumab was accompanied by the clearance of myeloma cells,” said Dr. Torben Plesner from the Vejle Hospital in Denmark, who presented the findings from the daratumumab trial at the 2012 American Society of Hematology (ASH) meeting last month.
“Daratumumab …
News»
This year’s meeting of the American Society of Hematology (ASH) was held December 8 through 11 in Atlanta.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting. After the meeting concluded, The Beacon began publishing in-depth articles about the key research findings.
This article, however, shifts the focus to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did the research …
News»
This year’s American Society of Hematology (ASH) annual meeting, which is being held in Atlanta, began yesterday and goes through Tuesday.
Today’s myeloma-related presentations began this afternoon with three sessions of oral presentations. Two of the sessions focused on results from clinical trials, most of which studied drugs that are still under development as potential treatments for multiple myeloma. The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clinical trial results.
This article will summarize the first oral session about multiple myeloma treatments, …
News»
During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clinical trials involving a number of potential new drugs under development for the treatment of multiple myeloma.
In particular, results for newer, lesser known agents that are in the early stages of clinical development will take center stage. These agents include ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.
According to the recently …
NewsFlash »
Genmab and Janssen Sign License Agreement For Daratumumab For Multiple Myeloma – Danish biotechnology company Genmab has signed a license agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, allowing Janssen to further develop and market daratumumab for the treatment of multiple myeloma. Daratumumab belongs to the same class of drugs as elotuzumab and siltuximab, called monoclonal antibodies. Monoclonal antibodies signal the body's immune system to kill myeloma cells. Daratumumab recently showed promising activity in relapsed and refractory myeloma patients (see related Beacon news). It is currently being studied in Phase 1/2 trials, which will be completed by Genmab. According to the agreement, which could be worth more than $1 billion, Janssen will complete all additional development of daratumumab. For more information, please see the Johnson & Johnson press release.
Phase 1/2 Clinical Trial To Study Linsitinib In Relapsed And Refractory Myeloma Patients – The University Health Network of Toronto, in collaboration with the Multiple Myeloma Research Consortium and Japanese pharmaceutical company Astellas Pharma, is starting a Phase 1/2 trial of linsitinib in combination with Velcade (bortezomib) and dexamethasone (Decadron) in relapsed and refractory multiple myeloma patients. The trial, which will take place at the Princess Margaret Hospital in Toronto, is available to myeloma patients who have received at least one prior therapy. Linsitinib (ASP7487, OSI-906) is a protein that triggers cancer cell death by inhibiting insulin-like growth factor 1. Preclinical studies have shown linsitinib to be effective when given with Velcade. For more information, please see the clinical trial description.
Revlimid-Delanzomib-Dexamethasone Combination May Be Effective For Multiple Myeloma – Results from a preclinical study indicate that delanzomib (CEP-18770) in combination with Revlimid (lenalidomide) and dexamethasone may be an effective treatment for multiple myeloma. Specifically, researchers found that the three-drug combination limited cancer growth more than Revlimid-dexamethasone therapy alone. Delanzomib, like Velcade and Kyprolis (carfilzomib), is a proteasome inhibitor that prevents the breakdown of proteins in cancer cells, triggering their death. The results of the current study support previous preclinical findings that showed delanzomib is a viable alternative for patients who do not respond to Velcade. Based on their findings the study investigators recommend additional study of this three-drug therapy. For more information, please see the study in Leukemia Research.
HIV/AIDS Drug Zidovudine May Be Effective For Multiple Myeloma – Findings from a recent Brazilian study show that the HIV/AIDS drug zidovudine (Retrovir, also known generically as azidothymidine, or AZT) may be an effective treatment for multiple myeloma. Zidovudine was the first therapy in the United States approved for the treatment of HIV. In the current study, researchers showed that zidovudine triggers cancer cell death in human myeloma cell lines. The study investigators also reported that zidovudine significantly reduced the number of myeloma cells in mice. According to the Brazilian researchers, this is the first time zidovudine has been studied in the context of multiple myeloma, and they suggest that the drug be investigated further for the treatment of multiple myeloma. For more information, please refer to the study in Anticancer Agents in Medical Chemistry (abstract).
Press Releases»
Compound in Development for Multiple Myeloma
Horsham, PA (Press Release) – Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab. Daratumumab (HuMax®-CD38) is a human CD38 monoclonal antibody currently in Phase I/II studies in relapsed, refractory multiple myeloma.
"Janssen was one of the first companies to recognize the power and promise of monoclonal antibodies and today is a world leader in biologics. We look forward to applying that same …
News»
Interim results of an ongoing early-stage clinical trial indicate that daratumumab is safe as a treatment for relapsed and refractory multiple myeloma. In addition, daratumumab showed promising activity in the trial participants.
Dr. Torben Plesner of Vejle Hospital in Denmark presented the preliminary results of the Phase 1/2 study at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) on Monday.
“The efficacy [of daratumumab] looks very promising,” said Dr. Andrzej Jakubowiak, the director of the myeloma program at the University of Chicago, who was not involved in the …
